Attached files
file | filename |
---|---|
10-Q - KERYX BIOPHARMACEUTICALS INC | v201097_10q.htm |
EX-31.1 - KERYX BIOPHARMACEUTICALS INC | v201097_ex31-1.htm |
EX-31.2 - KERYX BIOPHARMACEUTICALS INC | v201097_ex31-2.htm |
EX-32.1 - KERYX BIOPHARMACEUTICALS INC | v201097_ex32-1.htm |
Exhibit
32.2
STATEMENT
OF CHIEF FINANCIAL OFFICER OF
KERYX
BIOPHARMACEUTICALS, INC.
PURSUANT
TO 18 U.S.C. SECTION 1350,
AS
ADOPTED PURSUANT TO
SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In
connection with the quarterly report of Keryx Biopharmaceuticals, Inc. (the
“Company”) on Form 10-Q for the period ended September 30, 2010 as filed with
the Securities and Exchange Commission (the “Report”), I, James F. Oliviero,
Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350,
as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, based on
my knowledge:
1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the
Securities Exchange Act of 1934; and
2)
The information contained in the Report fairly presents, in all material
respects, the financial condition and results of operations of the Company.
Date:
November 5, 2010
|
/s/ James F. Oliviero
|
||
James
F. Oliviero
Chief
Financial Officer
Principal
Financial and Accounting
Officer
|